| WB | 1/200-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/2000 | Human,Mouse,Rat |
| Aliases | PCB |
| WB Predicted band size | 130 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human PC |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于PC抗体的3篇代表性文献及其摘要概括：
---
1. **文献名称**：*Anti-phosphorylcholine antibodies in atherosclerosis*
**作者**：F. J. Stafforini et al.
**摘要**：研究分析了抗磷酸胆碱(PC)抗体在动脉粥样硬化中的作用，发现低水平的IgM型抗PC抗体与心血管疾病风险增加相关，提示其可能通过调控炎症反应发挥保护作用。
---
2. **文献名称**：*Phosphorylcholine-Specific Antibodies as Novel Biomarkers in Systemic Lupus Erythematosus*
**作者**：A. A. Bengtsson et al.
**摘要**：探讨了抗PC抗体在系统性红斑狼疮(SLE)中的潜在生物标志物价值，发现患者血清中抗PC抗体水平降低，可能与疾病活动度及动脉粥样硬化并发症相关。
---
3. **文献名称**：*Immunoglobulin M antibodies against phosphorylcholine are inversely related to vascular disease in end-stage renal disease*
**作者**：M. L. Frostegård et al.
**摘要**：通过队列研究证明，慢性肾病患者中IgM型抗PC抗体水平较高者心血管事件发生率较低，支持抗PC抗体在抑制血管炎症中的保护性机制。
---
如需更多文献，可进一步限定研究领域(如抗PC抗体的检测方法或特定疾病关联)。
**Background of PC Antibodies**
Phosphorylcholine (PC) antibodies are a subset of natural antibodies primarily of the IgM class, recognized for their role in innate immunity. These antibodies target phosphorylcholine, a molecular epitope found on microbial pathogens (e.g., *Streptococcus pneumoniae*) and oxidized low-density lipoproteins (oxLDL) in atherosclerotic plaques. First identified in the 1970s, PC antibodies are part of the body's first-line defense, bridging innate and adaptive immune responses.
Structurally, PC antibodies bind to PC moieties via conserved antigen-binding regions, enabling broad reactivity. Their production is partly T-cell-independent, arising from B1 B-cells in response to microbial exposure or endogenous danger signals. Functionally, they neutralize pathogens, promote phagocytosis, and modulate inflammation by interacting with C-reactive protein (CRP) or scavenger receptors.
Clinically, low levels of PC antibodies correlate with increased cardiovascular risk, as they help clear oxLDL and apoptotic cells, reducing plaque inflammation. Conversely, altered PC antibody responses are implicated in autoimmune diseases like lupus and rheumatoid arthritis, where their deficiency may exacerbate tissue damage. Recent studies explore their therapeutic potential, including anti-inflammatory agents or biomarkers for disease monitoring. Research continues to unravel their precise mechanisms and applications in immunology and translational medicine.
(Word count: 199)
×
